a Department of Pathology , Massachusetts General Hospital, Harvard Medical School , Boston , Massachusetts , USA.
b Department of Urology , Massachusetts General Hospital, Harvard Medical School , Boston , Massachusetts , USA.
Cancer Biol Ther. 2018 Mar 4;19(3):175-180. doi: 10.1080/15384047.2017.1414762. Epub 2018 Jan 17.
Putative gender differences in bladder cancer (BCa) have been proposed to result from sex hormone influence. Aromatase is the key enzyme catalyzing the conversion of androgens to estrogens which may result in an intratumoral microenviroment with increased estrogen production. In this study, we investigated the expression pattern of aromatase and its association with BCa progression. Tissue samples from 88 BCa patients who underwent cystectomy were obtained. Using immunohistochemistry (IHC), expression of aromatase in tumor epithelium (TE) and tumor related stroma (TS) were evaluated separately, and the association of aromatase expression status with pathologic variables and overall survival (OS) outcome was examined. High aromatase expression was found in 33/88 (37.5%) of TE and in 65/88 (73.9%) of TS. Increased aromatase expression in TE had a trend to correlate with male gender. Increased aromatase in TS was significantly associated with adverse pathologic variables including higher pathologic pT, positive lymph node metastasis (pN), lymphovascular invasion (LVI), and distant metastasis. In univariate analysis, high aromatase expression in TS was significantly associated with poorer overall survival (p = 0.014), but this association was not significant (p = 0.163) in multivariate cox analysis adjusted for independent factors including age at surgery and pN. These results demonstrate that aromatase expression in TS but not TE may play a critical role in BCa progression. Our findings provide direct evidence of aromatase involvement in BCa and suggest endocrine therapy may have a potential role in the treatment of BCa.
已经提出膀胱癌 (BCa) 中的假定性别差异是由于性激素的影响所致。芳香酶是催化雄激素转化为雌激素的关键酶,这可能导致肿瘤内微环境中雌激素产生增加。在这项研究中,我们研究了芳香酶的表达模式及其与 BCa 进展的关系。对 88 例接受膀胱切除术的 BCa 患者的组织样本进行了研究。通过免疫组织化学 (IHC),分别评估了肿瘤上皮 (TE) 和肿瘤相关基质 (TS) 中芳香酶的表达,并检查了芳香酶表达状态与病理变量和总生存 (OS) 结果的关系。在 88 例 TE 中有 33 例 (37.5%) 和在 88 例 TS 中有 65 例 (73.9%) 发现芳香酶高表达。TE 中芳香酶表达增加与男性性别呈趋势相关。TS 中芳香酶的增加与不良病理变量显著相关,包括更高的病理 pT、阳性淋巴结转移 (pN)、淋巴血管侵犯 (LVI) 和远处转移。在单因素分析中,TS 中芳香酶高表达与总体生存率较差显著相关 (p = 0.014),但在调整手术时年龄和 pN 等独立因素的多因素 Cox 分析中,这种相关性不显著 (p = 0.163)。这些结果表明,TS 中芳香酶的表达而不是 TE 中芳香酶的表达可能在 BCa 的进展中起关键作用。我们的研究结果提供了芳香酶参与 BCa 的直接证据,并表明内分泌治疗可能在 BCa 的治疗中具有潜在作用。